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Signal transduction and gene regulation determine a major reorganization of metabolic
 
activities in order to support cell proliferation. Protein Kinase B (PKB), also known as Akt,
 
participates in the PI3K/Akt/mTOR pathway, a master regulator of aerobic glycolysis and
 
cellular biosynthesis, two activities shown by both normal and cancer proliferating cells.
 
Not surprisingly considering its relevance for cellular metabolism, Akt/PKB is often found
 
hyperactive in cancer cells. In the last decade, many efforts have been made to improve the
 
understanding of the control of glucose metabolism and the identification of a therapeutic
 
window between proliferating cancer cells and proliferating normal cells. In this context,
 
we have modeled the link between the PI3K/Akt/mTOR pathway, glycolysis, lactic acid
 
production, and nucleotide biosynthesis. We used a computational model to compare two
 
metabolic states generated by two different levels of signaling through the PI3K/Akt/mTOR
 
pathway: one of the two states represents the metabolism of a growing cancer cell charac-
 
 
terized by aerobic glycolysis and cellular biosynthesis, while the other state represents the  
same metabolic network with a reduced glycolytic rate and a higher mitochondrial pyruvate  
metabolism. Biochemical reactions that link glycolysis and pentose phosphate pathway  
revealed their importance for controlling the dynamics of cancer glucose metabolism.  
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INTRODUCTION
Growth factors and nutrients are required for cell growth and pro-
liferation in multicellular organisms. As a consequence of growth
factors withdrawal normal cells undergo apoptosis, while most
transformed cells escape the regulatory mechanisms and acquire
the ability to proliferate even in the absence of growth signals
(Edinger, 2005). In both normal and cancer cells the onset of
proliferation induces important changes in cellular metabolism.
Therefore metabolic activities in proliferating cells are fundamen-
tally different from those in non-proliferating cells (DeBerardinis
et al., 2008; Lunt and Vander Heiden, 2011).
The correlation between signal transduction pathways and cel-
lular metabolism is mediated by some key components of the
growth factor-induced cascades; typically these elements are pro-
tein kinases at the core of physiology and disease. Several growth
factor-induced signal transduction pathways have been charac-
terized so far and, in particular, the phosphoinositide 3-kinase
(PI3K) is a key component downstream of the receptor tyro-
sine kinases (RTKs; Cantley, 2002). The PI3K is responsible for
the production of 3-phosphoinositide lipid second messengers
including phosphoinositol trisphosphate (PIP3) at the cell mem-
brane. PIP3, in turn, contributes to the recruitment and acti-
vation of a wide range of downstream targets, among which
the serine-threonine protein kinase Akt, also known as protein
kinase B (PKB; Nicholson and Anderson, 2002; Gonzalez and
McGraw, 2009). Akt/PKB is phosphorylated at two sites, one
within the T-loop of the catalytic domain by the phosphoinositide-
dependent kinase 1 (PDK1) and the other within the car-
boxyl terminal hydrophobic domain by the mammalian target of
rapamycin complex 2 (mTORC2; Alessi et al., 1997; Sarbassov
et al., 2005).
Fully activated Akt/PKB translocates from the cell membrane
to the cytosol and nucleus where it phosphorylates its sub-
strates (Manning and Cantley, 2007) to regulate multiple func-
tions including cellular metabolism (Figure 1A). One of the chief
mechanisms of Akt/PKB promoting cell growth and prolifera-
tion is through the activation of mTOR complex 1 (mTORC1),
which is regulated by both nutrients and growth factor signaling
(Wullschleger et al., 2006; Zoncu et al., 2011). Moreover, mTORC1
directly enhances the transcriptional activity of hypoxia-inducible
factor 1α (HIF-1α; Land and Tee, 2007). HIF-1α is known to con-
trol the expression of several genes involved in energy metabolism,
apoptosis, angiogenesis, and metastasis (Carmeliet et al., 1998;
Pugh and Ratcliffe, 2003; Marín-Hernández et al., 2009).
Negative regulation of the PI3K/Akt/PKB pathway is primarily
accomplished through the action of the PTEN tumor suppres-
sor protein, a lipid and protein phosphatase whose main lipid
substrate is PIP3 (Song et al., 2012). Recently, a crucial mTORC1-
dependent feedback mechanism has been elucidated (Howell and
Manning, 2011). According to the current knowledge mTORC1
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FIGURE 1 |The PI3K/Akt/mTOR pathway regulates central carbon
metabolism. (A) PI3K/Akt/mTOR pathway. Signaling through the
PI3K/Akt/mTOR pathway begins with the activation of RTKs in response to
growth factors, leading to auto-phosphorylation on tyrosine residues and
trans-phosphorylation of adaptor proteins. The PI3K is responsible for the
production of 3-phosphoinositide lipid second messengers, including PIP3,
which contributes to the activation of many downstream targets, such as
PDK1 and mTORC2. Both PDK1 and mTORC2 activate, through
phosphorylation in different sites, the serine-threonine protein kinase Akt. Akt
regulates multiple functions including cellular metabolism, by promoting cell
growth and proliferation through the activation of mTORC1, which also
enhances the transcriptional activity of HIF-1α. Dashed lines represent the
negative regulation of the PI3K/Akt/mTOR pathway by the action of mTORC1
feedback mechanism. (B) The metabolic network with the main reactions of
glucose metabolism. A schematic representation of the glucose metabolism
network, using the SBGN notation (Le Novère et al., 2009), is presented. The
main pathways involved in the glucose metabolism are considered: glycolysis,
PPP, the glycogen synthesis and degradation, lactate, and MPM branches. The
metabolic targets regulated by PI3K/Akt/mTOR pathway are represented on
the network: the PI3K/Akt/mTOR direct regulation is presented in yellow; the
PI3K/Akt/mTOR indirect regulation (via HIF-1α) is presented in pink; the
PI3K/Akt/mTOR direct and indirect regulation is presented in orange. All the
PI3K/Akt/mTOR direct and indirect targets considered here are positively
regulated, with the only exception of the MPM. Allosteric regulators
(modifiers), activators (+), or inhibitors (−), are depicted in red.
Metabolites – ADP, adenosine diphosphate; AMP, Adenosine Monophosphate;
ATP, Adenosine Triphosphate; BPG, 1,3-bisphosphoglycerate; DHAP,
dihydroxyacetone phosphate; E4P, erythrose-4-phosphate; F6P,
fructose-6-phosphate; F16P, fructose-1,6-bisphosphate; G1P,
glucose-1-phosphate; G6P, glucose-6-phosphate; GAP,
glyceraldehyde-3-phosphate; GLC_c, cytoplasmic glucose; GLC_e,
extracellular glucose; GLY, glycogen; LAC, lactate; NAD, nicotinamide adenine
dinucleotides; NADH, nicotinamide adenine dinucleotides; NADP,
nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine
dinucleotide phosphate; Pi, inorganic phosphate; PEP, phosphoenolpyruvate;
PG2, 2-phosphoglycerate; PG3, 3-phosphoglycerate; PGN,
6-phosphogluconolactone; PRPP, phosphoribosylpyrophosphate; PYR,
pyruvate; R5P, Ribose-5-phosphate; RU5P, ribulose-5-phosphate; X5P,
xylulose-5-phosphate; S7P, sedoheptulose-7-phosphate; reactions – AK,
adenylate Kinase; ATPase, ATP hydrolysis; DHase, NADH oxidation; DPHase,
NADPH oxidation; ENO, Enolase; G6PDH, glucose-6-P dehydrogenase;
(Continued )
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FIGURE 1 | Continued
GAPDH, glyceraldehyde dehydrogenase; GLUT, glucose transporter; GPa,
glycogen phosphorylase A; GPb, glycogen phosphorylase b; GS, Glycogen
synthase; FBA, fructose-6-P aldolase; HK, Hexokinase; LDH, lactate
dehydrogenase; MPM, mitocondrial pyruvate metabolism; PFK,
phosphofructo-kinase; PGDH, phoshogluconolactone dehydrogenase; PGI,
phosphoglucoisomerase; PGK, phosphoglycerate kinase; PGLM,
phosphoglucomutase; PGYM, 3-phosphoglycerate mutase; PK, pyruvate
kinase; PRPPS, phosphoribosylpyrophosphate synthetase; R5PI, ribose-5-P
isomerase; RUPE, ribulose-phosphate-3 epimerase; TAL, transaldolase; TKL,
transketolase, reaction I; TKL2, transketolase, reaction II; TPI,
triose-phosphate isomerase.
can exert a negative regulation of its upstream signaling molecules
as depicted in Figure 1A.
Overall, the role of the PI3K/Akt/PKB signaling pathway in
oncogenesis has been extensively investigated and altered expres-
sion or mutations of many components of this pathway have
been implicated in human cancer (Vivanco and Sawyers, 2002;
Carnero, 2010). Indeed, expression of constitutively active forms
of Akt/PKB can prevent cell death upon growth factor withdrawal.
PI3K/Akt/mTOR-mediated survival relies on a profound meta-
bolic adaptation, including aerobic glycolysis (known as Warburg
effect).
In the last decade, many efforts have been made to improve
the understanding of the control of glucose metabolism. High-
rate glycolysis is supported by a number of molecular alterations,
which are either unique to cancer in an otherwise healthy organism
or druggable with controllable toxicities (Porporato et al., 2011). In
general, the goal is to find a therapeutic window between prolifer-
ating cancer cells and proliferating normal cells (Vander Heiden,
2011) in the development of successful cancer therapies target-
ing cellular metabolism. To be an attractive candidate for cancer
therapy, there must be a significant difference in enzyme activity
between cancer cells and normal proliferating cells (Hamanaka
and Chandel, 2012).
In this context, we have modeled the link between the
PI3K/Akt/mTOR pathway and metabolism, specifically the gly-
colytic rate, lactic acid production, and nucleotide biosynthesis.
Computational models are a tool to understand, control, and
predict the complex behavior of biological systems; for example,
computer-based simulations can be a powerful alternative to wet
experiments for exploring the impact of perturbations, such as
drug treatments, on a molecular network (Kreeger and Lauffen-
burger, 2010). Indeed, dynamical modeling of complex biological
systems has been widely used in the last decade. In particular, Ordi-
nary Differential Equations (ODEs) have been exploited as a stan-
dard numerical method in many successful examples (Novak and
Tyson, 1993; Tyson et al., 2001; Bazil et al., 2010). Before becoming
a predictive tool, a model must be defined and corroborated con-
sidering the available knowledge and experimental data. However,
current experimental techniques limit our ability to obtain in vivo
information about some aspects of metabolic pathways. In fact,
while metabolic fluxes can be measured in vivo using metaboli-
cally active molecules labeled with stable isotopes, it is hard or even
impossible to obtain accurate in vivo measures of enzyme prop-
erties. Therefore no existing experimental dataset contains all the
information for the biochemical processes and molecular species
under analysis. Nevertheless, several experimental datasets, col-
lected using a variety of tissue sources, techniques and experimen-
tal conditions (e.g., in vitro), are available for metabolic pathways.
Therefore, these data can be carefully integrated to fill the lack of
information, so that models can be optimized by means of various
simulation and analysis tools (Ghosh et al., 2011). With the addi-
tion of new experimental datasets, the model is refined through
possible modifications of its structure or parameter values.
Several models have been developed to describe the glucose
metabolism (Mosca et al., 2012). To study the accelerated glycolysis
of human cancer cells, Marín-Hernández et al. (2011) constructed
a model supported by experimental data for enzyme kinetics,
steady state pathway metabolite concentrations, and metabolic
fluxes. This model was used as the base model for our work due to
the type of cells used (a human cancer cell line) and the amount of
experimental data collected in the same condition. To accomplish
the task of modeling the metabolic effects of the PI3K/Akt/mTOR
pathway, we extended the network configuration and replaced
simplified rate equations for glycolytic branches with thermody-
namically consistent and detailed representations. Subsequently,
some parameter values were optimized to obtain a quantitative
reproduction of the metabolic state (fluxes and metabolites) of a
proliferating cancer cell line. In the resulting extended model, we
modulated the activity of PI3K/Akt/mTOR in order to simulate
the effects of the kinase levels over the rates of the processes con-
trolled by its (direct and indirect) targets. Then, we identified the
reactions exerting a major control over the metabolic network at
two different rates of glucose metabolism, corresponding to high
and low PI3K/Akt/mTOR activity. Enzymes that have a different
relevance in the two metabolic states represent potential targets
for a more selective control of the system.
RESULTS
MODEL DEVELOPMENT
The model represents the dynamics of the metabolic network
composed by the main metabolites and biochemical processes
(transports and reactions) of the glucose metabolism: the glucose
transport, the glycolytic reactions, the lactic acid production, the
glycogen synthesis/degradation, and the pentose phosphate path-
way (PPP; Figure 1B). The rates of the biochemical processes con-
sidered in the model are defined by taking into account the details
of the respective kinetic mechanisms. Therefore, the main activa-
tors and inhibitors forming feedback and feedforward regulations
are also considered. To maintain thermodynamic consistency and
since equation simplification by irreversibility limits the possi-
ble steady states allowed in the system, biochemical processes are
represented as thermodynamically balanced and reversible. This
approach was also important to enable the reproduction of the
wide range of glycolytic rates observed in relation to the regulatory
activities operated by oncogenes (Levine and Puzio-Kuter, 2010).
The only exception is the ATPase reaction, which is used here
as elsewhere (e.g., Lambeth and Kushmerick, 2002; Bazil et al.,
2010; Marín-Hernández et al., 2011) to simulate, with a unique
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flux, all the ATP consuming reactions that are not detailed in the
model.
The model is a 28 state system of differential algebraic equa-
tions (DAEs) that consists in 25 ODEs and 3 algebraic equations to
calculate ADP, NADH, and NADPH concentrations (see Appen-
dix). As previously mentioned, this model is primarily based on
a recent cancer glycolysis model of human cervical cancer HeLa
cells (Marín-Hernández et al., 2011). The model of HeLa cells
glycolysis was developed to reproduce a specific metabolic steady
state, making use of detailed rate equations for glycolysis and sim-
plified irreversible reactions for the PPP, the glycogen synthesis
and degradation, and the mitochondrial pyruvate metabolism
(MPM) branches. Since these glycolytic branches also play an
important role in relation to the metabolic states determined
by PI3K/Akt/mTOR signaling, we extended the network of reac-
tions substituting simplified branches with thermodynamically
balanced and reversible kinetics. In particular, rate equations for
PPP, glycogen synthesis, and degradation were defined as in the
model of Holzhütter (2004); the kinetics of phosphoglucomutase
(PGLM) and glycogen synthase (GS) were derived from Li et al.
(2010b); the glycogen phosphorylase (GP) kinetics from Lambeth
and Kushmerick (2002); the MPM was defined using a com-
mon modular rate law (Liebermeister et al., 2010). The model
is available in BioModels database (Li et al., 2010a) with identifier
MODEL1210150000.
MODEL FITTING
The model was optimized assembling a dataset that represents the
typical traits of a cancer cell growing in condition of non-limiting
glucose: increased glycolytic rate, active synthesis of NADPH and
nucleotides, predominant metabolization of glucose to lactate
rather than to CO2 and H2O through the tricarboxylic acid cycle
(Levine and Puzio-Kuter, 2010).
As in several other recent computational models of metabolic
pathways (e.g., Bazil et al., 2010; Li et al., 2010b), we adjusted only
a small subset of the parameters appearing in the model equa-
tions and, more precisely, we focused on the maximum rates of
forward reactions (Table 1). Biologically, this can be interpreted
Table 1 | Maximum reaction rates in conditions H and L.
Reaction Definition Condition H Condition L
V f (nmol/min/mg) s V f (nmol/min/mg) s
AK Adenylate kinase 1.412e+02 3.449e−02 1.412e+02 3.449e−02
ATPasea ATP hydrolysis 6.210e+03 2.292e−01 6.210e+03 2.373e−01
DHase NADH oxidation 4.982e+06 1.171e−03 4.982e+06 2.278e−03
DPHase NADPH oxidation 1.278e+05 6.963e−02 7.413e+04 3.430e−02
ENO Enolase 1.609e+02 3.627e−04 9.330e+01 4.074e−04
FBA Fructose-6-P aldolase 1.463e+01 6.639e−04 8.484e+00 1.491e−03
G6PDH Glucose-6-P dehydrogenase 1.008e+00 1.181e+00 5.846e−01 7.600e−01
GAPDH Glyceraldehyde dehydrogenase 1.091e+02 2.345e−02 6.329e+01 2.696e−02
GLUT Glucose transporter 2.303e+01 4.271e−01 1.336e+01 5.256e−01
GPa Glycogen phosphorylase a 3.347e−02 3.602e−02 3.347e−02 3.790e−02
GPb Glycogen phosphorylase b 1.049e−02 3.679e−02 1.049e−02 3.962e−02
GS Glycogen synthase 3.204e+04 3.934e−02 1.858e+04 6.016e−02
HK Hexokinase 8.685e+01 7.173e−02 5.037e+01 5.998e−02
LDH Lactate dehydrogenase 3.403e+02 3.331e−03 1.974e+02 3.647e−03
MPM Mitochondrial pyruvate metabolism 9.801e+06 1.142e−01 1.137e+07 1.423e−01
PFK Phosphofructo-kinase 1.076e+02 5.706e−02 6.243e+01 1.138e−01
PGDH Phoshogluconolactone dehydrogenase 3.102e+01 5.136e−03 1.799e+01 6.160e−04
PGI Phosphoglucoisomerase 7.778e+03 3.709e−02 4.511e+03 3.216e−03
PGK Phosphoglycerate kinase 7.341e+01 8.065e−03 4.258e+01 9.261e−03
PGLM Phosphoglucomutase 7.364e+00 3.351e−02 7.364e+00 1.651e−02
PGYM Phosphoglycerate mutase 1.540e+02 2.232e−03 1.540e+02 2.489e−03
PK Pyruvate kinase 2.781e+01 1.070e−07 1.613e+01 4.182e−07
PRPPS Phosphoribosylpyrophosphate synthetase 5.104e+01 5.898e−01 5.104e+01 5.439e−01
R5PI Ribose-5-P isomerase 7.646e+01 2.643e−02 7.646e+01 6.134e−02
RUPE Ribulose-phosphate epimerase 1.471e+00 1.156e−03 1.471e+01 2.467e−03
TAL Transaldolase 5.827e+01 7.061e−04 5.827e+01 1.040e−04
TKL Transketolase (reaction I) 1.056e+03 5.345e−04 6.124e+02 1.180e−03
TKL2 Transketolase (reaction II) 1.761e+01 4.674e−01 1.021e+01 2.420e−02
TPI Triose-phosphate isomerase 5.976e+00 2.779e−04 3.466e+00 6.055e−04
Maximum rates of the forward reactions (Vf) and mean first-order local sensitivities (s) of steady state fluxes in relation to perturbation of Vf values. amin−1mg−1.
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as the correction of enzyme concentrations or enzyme activities
in order to explain, with the equations used in the model, the
metabolic values (fluxes and concentrations) measured experi-
mentally. Crucially, by constructing the model taking into account
the Haldane constraint, which relates the equilibrium constant of
a biochemical reaction with (forward and reverse) maximum rates
and reactant constants (Appendix), the adjustment/optimization
of the parameter values will not violate the thermodynamics of
any reaction or of the entire network (Lambeth and Kushmer-
ick, 2002), but only physiologically appropriate kinetic parameter
values will result in reasonable fluxes and accurate dynamics.
Metabolite concentrations and metabolic fluxes were primarily
collected from two experimental studies on human cervix cancer
HeLa cells (Reitzer et al., 1980; Marín-Hernández et al., 2011).
Reitzer et al. (1980) measured the flux of sugar carbon per unit
of protein synthesized in the major pathways of metabolism of
HeLa cells growing on 10 mM glucose. Under this condition, they
observed that the 10% of the glucose converted to glucose-6-P,
which was quantified as 11.3 nmol/min/mg, is diverted toward
the oxidative arm of the pentose cycle, 5% to purine metabolism
and nucleotide biosynthesis, 1% to glycogen, and 80% to lactate
(Figure 2A). The optimized model provided a satisfactory repre-
sentation of the experimental data considered, in terms of fluxes
(Figure 2A) and metabolite concentrations (Figure 2B).
IN SILICO MODULATION OF PI3K/Akt/mTOR ACTIVITY
We considered the most established metabolic targets regulated
by PI3K/Akt/mTOR and by HIF-1α, as indicated in Figure 1B.
The PI3K/Akt/mTOR pathway activation increases the synthesis
of GLUT, the main glucose transporter in most cell types (Kohn
et al., 1996), and enhances its transcription and its transloca-
tion from the cytosol to the plasma membrane, increasing glu-
cose uptake (Barthel et al., 1999; Rathmell et al., 2003). Upon
PI3K/Akt/mTOR stimulation, the activity of the hexokinase (HK)
is enhanced (Elstrom et al., 2004). PI3K/Akt/mTOR has also
effects on other steps of glycolysis; in fact, it has been shown that
increasing GLUT and HK expression does not enhance the gly-
colytic flux to the observed levels with constitutive activation of
PI3K/Akt/mTOR (Rathmell et al., 2003). Glycolysis downstream
targets of PI3K/Akt/mTOR include PFK2; phosphorylation and
activation of PFK2 lead to allosteric activation of PFK1 (Deprez
et al., 1997). Moreover, PI3K/Akt/mTOR inhibits GSK, the GS
kinase-3beta (Yoeli-Lerner et al., 2009), which inhibits the GS; as a
consequence, PI3K/Akt/mTOR has indirect positive effects on the
glycogen synthesis. Also the ATP-citrate lyase, the primary enzyme
responsible for the synthesis of cytosolic acetyl-CoA, is a sub-
strate for PI3K/Akt/mTOR (Berwick et al., 2002). An important
target of PI3K/Akt/mTOR is HIF-1α, which can be overexpressed
also under non-hypoxic conditions through PI3K/Akt/mTOR (Lee
et al., 2008); in turn, HIF-1α is responsible for the positive regula-
tion of several enzymes of the central metabolism: almost all the
glycolytic enzymes (Semenza et al., 1994), G6PDH, PGDH (Guo
et al., 2009), TKL (Zhao et al., 2010), and LDH (Firth et al., 1995);
HIF-1α also stimulates the inhibition of PDH (Biswas et al., 2010).
To model the metabolic effects of the PI3K/Akt/mTOR signal-
ing pathway, we modified the rate equations for the biochemical
FIGURE 2 | Metabolic fluxes and metabolite concentrations. (A) A
Simplified illustration of the metabolic network, where the width of the
arrows is proportional to the predicted flux values, which are reported close to
the respective arrows; experimental values are shown in parentheses; fluxes
are in nmol/min/mg unit. (B) Predicted (white) and experimental (black)
metabolite concentrations, reported as the log10 of nM values. The full list of
predicted and experimental fluxes and concentration values in conditions H
and L is available in the Appendix.
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processes regulated by the targets of PI3K/Akt/mTOR. Rate
equations were modified on the basis of the specific effect
PI3K/Akt/mTOR exerts over each of its targets. If PI3K/Akt/mTOR
positively (negatively) regulates the protein concentration, we
increased (decreased) the value of the maximum rate of the for-
ward reaction (V f) of the corresponding process, because this
quantity is directly proportional to the total protein concentration
(Sauro, 2011). This is the case of GLUT, GS, glycolytic enzymes,
and PPP enzymes (Figure 2). The enhancement of PFK activity
mediated by PI3K/Akt/mTOR is also exerted through F26P, one of
PFK allosteric activators, and therefore we increased the F26P con-
centration. The positive relation between PI3K/Akt/mTOR and
fatty acid synthesis was taken into account increasing the rate
of NADPH consuming reactions (fatty acid synthesis requires
NADPH), while the inhibition of PDH due to PI3K/Akt/mTOR
was simulated reducing the rate of the MPM process.
Starting from the metabolic state representing the typical traits
of a cancer cell growing in condition of non-limiting glucose
(Figure 2) and modulating PI3K/Akt/mTOR activity, we obtained
several metabolic steady states (Figure 3). Coherently with what
is observed experimentally (DeBerardinis et al., 2008), the flux
through glycolysis, glycogen synthesis, and the portion of pyru-
vate metabolized toward lactate increased as the PI3K/Akt/mTOR
activity was increased and vice versa. We considered two meta-
bolic steady states as representatives of two different glycolytic
rates, corresponding to high or low PI3K/Akt/mTOR activity:
the first, representing a cancer cell line where PI3K/Akt/mTOR
promotes a high-rate of glucose metabolism (Figures 2 and 3,
condition H); the second characterized by a lower glycolytic
rate due to a reduced PI3K/Akt/mTOR signal (Figure 3, condi-
tion L).
In relation to condition H, condition L was selected for its rea-
sonable reproduction of the available experimental data and for
conserving the direction of the metabolic fluxes. In fact, on the
one hand the variation of glycolysis and lactic acid production
rate between state H and L was respectively of ∼1.7- and ∼2.0-
fold (Figure 3; Appendix), close to the respective values of ∼1.5
and ∼3.0 recently measured by Fan et al. (2010) after activation
of Akt. On the other hand, by conserving the same flux direc-
tion between conditions H and L we were able to exclude effects
FIGURE 3 | Lower metabolic fluxes are obtained reducing PI3K/Akt/mTORs activity. Time variation of some representative fluxes (nmol/min/mg) before
(condition H) and after the reduction of PI3K/Akt/mTOR signaling (at t ( 7dd). The thick lines indicate the dynamics that lead to the representative condition L
(right).
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due to a different configuration of the flow of mass within the
system, enabling a meaningful comparison focused on metabolic
rates between two states that reproduce the metabolic variations
measured in relation to PI3K/Akt/mTOR activity (for instance,
other possible configurations could be: the non-oxidative arm of
the PPP that extracts part of the glycolytic flux and redirects it
toward nucleotide biosynthesis; glycogen degradation higher than
glycogen synthesis).
LOCAL SENSITIVITY ANALYSIS
A first-order sensitivity analysis (SA) on the model was performed
to determine how robust the steady states under analysis were
in relation to local perturbations in the parameter values. These
sensitivity indexes represent a measure of the degree to which
the steady states H and L are sensitive to the value of individ-
ual parameters. A high sensitivity value indicates that changing
a given parameter determines significant changes to the consid-
ered dynamics. The averages (median) of the sensitivity indexes,
of all the 29 adjustable parameters, are respectively 3.198e-03 and
7.320e-04 for conditions H and L (Table 1). Therefore, on average
a small perturbation of a given parameter determines a change
in the steady state fluxes that is approximately three orders of
magnitude less than the perturbation.
COMPARISON OF THE ENZYME CONTROL OVER THE SYSTEM AT
DIFFERENT RATES OF GLUCOSE METABOLISM
To study the global sensitivity of conditions H and L in rela-
tion to each biochemical process of the metabolic network (listed
in Table 1), we calculated, for each possible pairs of biochem-
ical processes, the Derivative Based Global Sensitivity Measures
(DGSMs; Kucherenko et al., 2009) that summarize the (total)
effect exerted by a reaction on the steady state flux of another reac-
tion around the metabolic steady states H and L. Conversely form
the Metabolic Control Analysis (MCA; Fell, 1997), DGSMs are a
method for SA that copes with model non-linearities and interac-
tions between the quantities under analysis. In fact, this method
does not require a linearization of the system and considers the
effect of perturbing more than one quantity at the same time, but
it is computationally more intensive than MCA (see Materials and
Methods).
In state H, steady fluxes are more sensitive to enzymes of the
PPP (Figure 4A): G6PDH, first enzyme of the PPP and also
target of p53 (Jiang et al., 2011); PRPPS, which catalyzes the
phosphoribosylation of ribose-5-phosphate to 5-phosphoribosyl-
1-pyrophosphate, a metabolite that is necessary for purine metab-
olism and nucleotide biosynthesis; TKL, a thiamine-dependent
enzyme that channels sugar phosphates between glycolysis and
the PPP. GLUT, the source of mass of the system, also exerts
a major control. With the exceptions of HK, FBA, TPI, and
ENO, the variation of other glycolytic enzyme activity appears
to exert a similar effect on the steady state metabolic fluxes
in the two conditions. In condition L, steady state fluxes
are still sensitive to GLUT, G6PDH, and PRPPS, even if the
amount of control differs; in contrast, TKL loses its role and
PFK, HK, and ATPase emerge as important players for system
dynamics.
To identify the reactions exerting a different control over the
system when using the two conditions H and L, we calculated,
for each reaction, the normalized difference in the ranking of all
the reactions based on their relevance in state H and L. When
comparing the ranking of the sensitivity indexes between the two
metabolic steady states, we observed that the PPP enzymes G6PDH
FIGURE 4 | Heatmap of the steady state flux sensitivity to reactions. (A)
Sensitivities of the steady state fluxes (rows) in relation to the reactions
(columns) in condition H; red: high sensitivity; green: low sensitivity. (B)
Differential ranking of steady state flux sensitivities (rows) to reactions
(columns) when comparing conditions H and L; red: high sensitivity in
condition H; green: high sensitivity in condition L.
www.frontiersin.org November 2012 | Volume 3 | Article 418 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
and TKL showed a prominent role in condition H; ENO, respon-
sible of the conversion between PG2 and PEP, also had a relatively
higher control in H in comparison to L (Figure 4B). Conversely,
in condition L the system is more sensitive to GLUT, PFK, and to
some of the enzymes of the glycolytic “pay off” phase. This trend
is also evident when considering the top ranked enzymes for the
control of specific steps (Figure 5).
Another interesting question that arises with the type of SA we
have performed concerns the reactions having a high control over
a specific flux or set of fluxes. To this aim we calculated, for each
flux, the relative log sensitivity (see Materials and Methods). This
analysis underlined that glycolysis is specifically sensitive mainly
to GLUT, HK, and PGI (Figure 6).
Importantly, the structure of the metabolic network emerges
from the clustering of the quantities illustrated in Figures 4 and
6: SA indexes referring to the variation of steady state fluxes of
neighboring reactions are similar. This expected result is the con-
sequence of having performed the SA at steady state, where mass
conservation constrains the steady state fluxes of neighboring
reactions according to their stoichiometry.
DISCUSSION
Several computational models have been proposed to study the
control of the glycolytic flux. In Table 2 we summarized the main
results obtained by those works that we based the definition of our
model on. Marín-Hernández et al. (2006) performed an elasticity-
based control analysis of the glycolytic flux in rat hepatoma cells
(AS-30D); the authors observed that the major control of the glu-
cose metabolism is due to the upstream part of glycolysis (GLUT,
HK, GP, PGI, PFK). In a subsequent analysis based on a kinetic
model, the same group calculated that glycolysis is mainly con-
trolled by HK, HPI, and GLUT in AS-30D cells while glycogen
degradation, GLUT and HK are key steps for HeLa cells. Using
MCA, Schuster and Holzhutter (1995) calculated that the gly-
colytic flux in erythrocytes is mainly controlled by ATP utilization.
Several computational studies have been done on the glycolysis
of skeletal muscle cells. For example, Lambeth and Kushmerick
(2002) identified in GP and PK the main steps of glycolytic con-
trol at resting flux; PFK and PGLM become important when the
ATP utilization increases while GP activity gains importance in the
network as the glycolytic flux increases.
FIGURE 5 | Reactions exerting the most of the control over the metabolic network. Ranking of the top reactions having the highest influence on the flux of
GLUT (A), G6PDH (B), PRPPS (C), and LDH (D) in H (black) and L (white). A value of 1 corresponds to the best rank.
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FIGURE 6 | Heatmap of the relative log sensitivities of steady state fluxes (rows) in relation to reactions (columns) in condition H. Red: high sensitivity;
green: low sensitivity.
Table 2 | Major controller of glycolysis reported in other
computational and experimental works.
Major controller of glucose flux Experimental
conditions
Reference
ATP utilization Erythrocytes Schuster and
Holzhutter (1995)
ATPase, GP, PK, PFK, and PGLM Skeletal muscle Lambeth and
Kushmerick (2002)
GLUT, HK, PGI, PFK, G6P branches AS-30D Marín-Hernández
et al. (2006)
HK, HPI, GLUT AS-30D Marín-Hernández
et al. (2011)
Glycogen degradation, GLUT, HK HeLa Marín-Hernández
et al. (2011)
Comparison of the results obtained by different works should
be done taking into account the structure of the metabolic net-
work, the rate equations and the model configuration used. For
example, a relevant control of the glycogen degradation step over
the glycolytic flux was reported when glycogen was one of the
sources of glucose for the system, as in Marín-Hernández et al.
(2006) and Lambeth and Kushmerick, 2002 (Table 2). This was
not the scenario of condition H, but, despite the differences in
the metabolic network and metabolic state that we considered in
comparison to Marín-Hernández et al. (2011), we also found that
GLUT and HK exert a relevant control for glycolysis (Figure 6).
We compared two metabolic states generated by the spe-
cific variation of the fluxes regulated by the activity of the
PI3K/Akt/mTOR pathway. One state represented the metabo-
lism of a growing cancer cell characterized by aerobic glycolysis
and cellular biosynthesis (condition H), while the other (condi-
tion L) represented the same metabolic network with a reduced
glycolytic rate, a reduced lactic acid production, but a higher
MPM, as reported in literature in relation to a lower activity of
PI3K/Akt/mTOR (DeBerardinis et al., 2008). Some steps of the
metabolic network that link glycolysis and PPP, namely those cat-
alyzed by the G6PDH and TKL enzymes, revealed their importance
for the cancer metabolic state. Results from our model may pro-
vide insight and assist in the selection of drug targets in anticancer
treatments.
Results gained with current models in biology are still restricted
by the assumptions made in relation to the limits of the current
technologies, the lack of detailed information collected in the same
experimental conditions and the need to simplify biological com-
plexity (aspects as enzymes isoforms, molecular crowding and
the temporal variation of enzyme concentration are usually not
accounted for). Nevertheless, considering that model definition
is related to the questions the modeler wants to answer, current
models can be a useful tool for directing experimental efforts on a
subset of all possible hypotheses. In relation to the crucial steps that
emerged in this work for the dynamics of the metabolic network, it
is worth to mention that, recently, several authors have recognized
G6PDH and TKL as potential anticancer targets (e.g., Tennant
et al., 2010; Vander Heiden, 2011). In general, there are several
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leading therapeutic compounds targeting glucose metabolism in
preclinical and clinical phases for many tumor types, such as solid
tumors (lung, breast, prostate, gastric), metastatic melanoma and
renal cell carcinoma (Tennant et al., 2010; Porporato et al., 2011;
Vander Heiden, 2011). Other principal targets that are currently
enrolled in clinical and/or preclinical studies are: GLUT, HK, PK,
LDH (preclinical and clinical; Mohanti et al., 1996; Singh et al.,
2005; Christofk et al., 2008; Mathupala et al., 2009; Le et al., 2010;
Wolf et al., 2011); PFK, PGYM, TKL, G6PDH (preclinical only;
Kuo et al., 2000; Evans et al., 2005; Clem et al., 2008; Furuta et al.,
2010).
It would be interesting to extend our analysis in order to
compare other representative steady states, such as, for example,
those considered by Sengupta et al. (2011), who evaluated differ-
ent glucose metabolization patterns between glycolysis and PPP
in growing and non-growing conditions. Moreover, our current
model could be linked to a model of mitochondrion (e.g., Bazil
et al., 2010) in order to include detailed representations of the tri-
carboxylic acid cycle and other relevant metabolic reactions that
take place in the mitochondrion.
MATERIALS AND METHODS
NUMERICAL SOLUTIONS
The DAE system representing the metabolic network was numer-
ically integrated using MATLAB (2008b) and the stiff ode solver
ode15s with absolute and relative tolerances of 10−9 and 10−6
respectively. Steady states were identified using the MATLAB func-
tion fsolve with default options. Model optimization and sensitiv-
ity analyses were done on HP(R) workstations equipped with two
2.50 GHz INTEL(R) Quad-core Xeon(R) E5420 processors and
10 GB RAM. The results obtained were displayed using MATLAB.
MODEL OPTIMIZATION
Recently, it has been observed that multi-objective optimization
have significant benefits compared to single objective approaches
(Handl et al., 2007). Model fitting was formulated as a multi-
objective optimization problem aiming at the simultaneous mini-
mization of the difference between model predictions and experi-
mentally determined concentrations, enzyme activities, and steady
state fluxes. In detail, two objectives [f1(x), f2(x)] were defined as
f1,2 (x) = 1/NΣi=1,...,N log10
(
xi/x
∗
i
)
subject to
J∗ = J (x)
x > 0
where x∗i is the experimental value for the concentration of a
metabolite (in the case of f1) or enzyme V mf (for f2), x i is the
corresponding value used in the model, N is the number of ele-
ments (metabolites or enzymes), J∗ is the vector of experimental
values of enzyme fluxes and J(x) are the respective model predic-
tions obtained using x. The multi-objective optimization problem
was solved using the Non-Dominated Sorting Genetic Algorithm
II (Deb et al., 2002), which is one of the most popular methods in
the field of multi-objective optimization. The NSGA-II algorithm
was run in parallel using several populations of 1000 individuals
for 100 generations. Every five generations, the worst five individ-
uals of a population were replaced by a random selection of the
best five individuals from the other populations.
MODELING THE METABOLIC EFFECTS OF PI3K/Akt/mTOR
The metabolic effects of PI3K/Akt/mTOR were modeled accord-
ing to the mechanism of interaction with its targets. Parameter
values used to create condition L were obtained from condition H,
multiplying a specific quantity appearing in the rate equation for
the biochemical process regulated by a target of PI3K/Akt/mTOR
by quantity α in order to reduce or increase the target activity.
In detail, for GLUT, HK, PGI, GS, G6PDH, PGDH, TAL, TKL,
TKL2, FBA, TPI, GAPDH, PGK, ENO, PK, LDH, and DPHase, we
multiplied the respective V f by α= 0.56, while for MPM we mul-
tiplied the respective V f by α= 1.16; for PFK, we also multiplied
the concentration of its allosteric activator F26P by α= 0.56. The
V f values used to obtain steady states H and L are listed in Table 1.
Rate equations are listed in Appendix.
SENSITIVITY ANALYSIS
Sensitivity analysis can be defined as the study of how uncertainty
in the output of a model can be apportioned to different sources
of uncertainty in the model input (Saltelli et al., 2000). In most of
the current systems biology literature, sensitivities indexes are esti-
mated calculating derivatives of a model output in a specific state
of the system (local approach) corresponding to a particular model
parameterization; moreover,only the variation of one parameter at
a time is considered. For example, control coefficients estimated in
the context of MCA are scaled partial derivatives calculated on the
model linearized around a steady state; thus, MCA quantifies how
a model output is influenced by infinitesimal changes in a parame-
ter. As a consequence, results of MCA are restricted to infinitesimal
parameter changes and do not account for interactions between
parameters.
To overcome this issue, especially considering that the bio-
logical quantities represented with parameters (e.g., the enzyme
concentration) are subject to significant variations, in our study
we carried out the SA calculating the DGSMs (Kucherenko et al.,
2009). The method is based on averaging local derivatives using
(quasi) Monte Carlo (MC) sampling.
To compute the DGSMs we generated, for each of the condi-
tions H and L, a set of parameterizations pk= (pk1, pk2, . . . , pkn),
n= 29, k = (1, 2, . . . , 500), pk ∈ [p− εp, p+ εp], where each pk
represents a possible perturbations of all the 29 V f reference val-
ues (p) reported in Table 1. This sampling was carried out using
the Sobol Sequences, a class of quasi-random low discrepancy
sequences (Sobol, 1967). The parameterizations pk were used to
calculate the elementary effects
e ijk = ∣∣[Ji(pk1, . . . , pkj + δ, . . . , pkn)− Ji(pk1, . . . , pkj , . . . , pkn)]∣∣/
δ · (pkj/
∣∣Ji(pk1, . . . , pkj , . . . , pkn)∣∣)
a measure of the impact of having introduced the perturbation δ
in the j-th element of pk on the steady state flux Ji, i= (1, 2, . . . ,
29). Hence, for each of the two conditions H and L, we obtained a
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total of 500 29-by-29 matrices of elementary effects that were used
to calculate the 29-by-29 matrices of scaled sensitivity indexes
gij =
(
m2ij + s2ij
)/
Σj=1,...,29
(
m2ij + s2ij
)
where mij and sij are, respectively, the mean and sample standard
deviation of the elementary effects eijk.
The normalized differential ranking of the reactions was
calculated as
Rij =
(
rLij − rHij
)/(
rLij + rHij
)
where rij= (1, 2, . . . , 29) is the rank of the scaled sensitivity index
gij when ordering the elements (g i1, g i2, . . . , g i29) from the highest
(strong influence of parameter j on flux i) to the lowest, and the
superscript L or H indicates the condition. Hence, Rij will be posi-
tive (negative) for V f parameters (and the corresponding reaction)
exerting a higher (lower) control in condition H in relation to con-
dition L; Rij will be higher for reactions having a higher control in
both conditions.
The relative log sensitivity was calculated as
RLSij = log10
(
gij
/
m′i
)
and indicates the degree of variation of a scaled sensitiv-
ity index gij in relation to the median mi’ of all the scaled
sensitivity indexes related to the same V f parameter (g 1j , g 2j , . . . ,
g 29j ).
For each of the two conditions H and L, the 29-by-29 matrix
of the first-order local sensitivity indexes sij for steady state flux
i to perturbation of V f of reaction j was obtained by calculating
the elementary effects eijk using the respective values V f listed in
Table 1, that is pk= p.
We used ε= 5 · 10−6 and δ= 10−6; steady state fluxes Ji were
obtained by numerical integration of the DAE system within the
interval [0, 104], followed by the identification of the steady state
(see above the numerical solutions paragraph). For the calculation
of the DGSMs, 2N (n+ 1) numerical solutions of the model were
required, where N = 500 represents the number of parameteriza-
tions, n= 29 is the number of the parameters, and the factor 2 is
due to the two conditions H and L.
ACKNOWLEDGMENTS
The work was carried out under the HPC-EUROPA2 (228398)
projects with the support of the European Commission – Capac-
ities Area – Research Infrastructures, and under the Italian FIRB-
MIUR projects ITALBIONET (RBPR05ZK2Z), BIOPOPGEN
(RBIN064YAT), HIRMA (RBAP11YS7K), and INTEROMICS
Flagship Initiative. We thank Dr. I. Merelli of Institute for Bio-
medical Technologies (ITB-CNR) for his technical support with
high performance computing and thank John Hatton (ITB-CNR)
for proofreading the manuscript.
REFERENCES
Alessi, D. R., James, S. R., Downes, C. P.,
Holmes, A. B., Gaffney, P. R., Reese,
C. B., et al. (1997). Characterization
of a 3-phosphoinositide-dependent
protein kinase which phosphorylates
and activates protein kinase Balpha.
Curr. Biol. 7, 261–269.
Barthel, A., Okino, S. T., Liao, J.,
Nakatani, K., Li, J., Whitlock, J.
P. Jr. et al. (1999). Regulation of
GLUT1 gene transcription by the
serine/threonine kinase Akt/PKB1. J.
Biol. Chem. 274, 20281–20286.
Bazil, J. N., Buzzard, G. T., and
Rundell, A. E. (2010). Model-
ing mitochondrial bioenergetics
with integrated volume dynamics.
PLoS Comput. Biol. 6, e1000632.
doi:10.1371/journal.pcbi.1000632
Berwick, D. C., Hers, I., Heesom,
K. J., Moule, S. K., and Tavare,
J. M. (2002). The identification
of ATP-citrate lyase as a protein
kinase B (Akt/PKB) substrate in pri-
mary adipocytes. J. Biol. Chem. 277,
33895–33900.
Biswas, S., Troy, H., Leek, R., Chung,
Y. L., Li, J. L., Raval, R. R., et al.
(2010). Effects of HIF-1alpha and
HIF2alpha on growth and metab-
olism of clear-cell renal cell carci-
noma 786-0 xenografts. J. Oncol.
2010, 757908.
Cantley, L. C. (2002). The phospho-
inositide 3-kinase pathway. Science
296, 1655–1657.
Carmeliet, P., Dor, Y., Herbert, J.
M., Fukumura, D., Brusselmans, K.,
Dewerchin, M., et al. (1998). Role
of HIF-1alpha in hypoxia-mediated
apoptosis, cell proliferation and
tumour angiogenesis. Nature 394,
485–490.
Carnero, A. (2010). The PKB/Akt/PKB
pathway in cancer. Curr. Pharm. Des.
16, 34–44.
Casazza, J. P., and Veech, R. L. (1986).
The interdependence of glycolytic
and pentose cycle intermediates in
ad libitum fed rats. J. Biol. Chem. 26,
690–698.
Christofk, H. R., Vander Heiden, M. G.,
Harris, M. H., Ramanathan, A., Ger-
szten, R. E., Wei, R., et al. (2008). The
M2 splice isoform of pyruvate kinase
is important for cancer metabolism
and tumour growth. Nature 452,
230–233.
Clem, B., Telang, S., Clem, A., Yal-
cin, A., Meier, J., Simmons, A.,
et al. (2008). Small-molecule inhi-
bition of phosphofructo-2-kinase
activity suppresses glycolytic flux
and tumor growth. Mol. Cancer
Ther. 7, 110–120.
Deb, K., Pratap, A., Agarwal, S., and
Meyarivan, T. (2002). A fast and
elitist multiobjective genetic algo-
rithm: NSGA-II. IEEE Trans. Evol.
Comp. 6, 182–197.
DeBerardinis, R. J., Lum, J. J., Hatzi-
vassiliou, G., and Thompson, C.
B. (2008). The biology of can-
cer: metabolic reprogramming fuels
cell growth and proliferation. Cell
Metab. 7, 11–20.
Deprez, J., Vertommen, D., Alessi, D.
R., Hue, L., and Rider, M. H.
(1997). Phosphorylation and acti-
vation of heart 6-phosphofructo-2-
kinase by protein kinase B and other
protein kinases of the insulin sig-
nalling cascades. J. Biol. Chem. 272,
17269–17275.
Edinger, A. L. (2005). Growth factors
regulate cell survival by control-
ling nutrient transporter expression.
Biochem. Soc. Trans. 33, 225–227.
Elstrom, R. L., Bauer, D. E., Buzzai,
M., Karnauskas, R., Harris, M. H.,
Plas, D. R., et al. (2004). Akt stim-
ulates aerobic glycolysis in cancer
cells. Cancer Res. 64, 3892–3899.
Evans, M. J., Saghatelian, A., Sorensen,
E. J., and Cravatt, B. F. (2005). Tar-
get discovery in small-molecule cell-
based screens by in situ proteome
reactivity profiling. Nat. Biotechnol.
23, 1303–1307.
Fan,Y., Dickman, K. G., and Zong, W. X.
(2010). Akt and c-Myc differentially
activate cellular metabolic pro-
grams and prime cells to bioener-
getic inhibition. J Biol Chem. 285,
7324–7333.
Fell, D. (1997). Understanding the Con-
trol of Metabolism. London: Portland
Press.
Firth, J. D., Ebert, B. L., and Ratcliffe,
P. J. (1995). Hypoxic regulation of
lactate dehydrogenase A. Interaction
between hypoxia-inducible factor 1
and cAMP response elements. J. Biol.
Chem. 270, 21021–21027.
Furuta, E., Okuda, H., Kobayashi, A.,
and Watabe, K. (2010). Metabolic
genes in cancer: their roles in tumor
progression and clinical implica-
tions. Biochim. Biophys. Acta 1805,
141–152.
Gao, H., and Leary, J. A. (2004). Kinetic
measurements of phosphoglucomu-
tase by direct analysis of glucose-1-
phosphate and glucose-6-phosphate
using ion/molecule reactions and
Fourier transform ion cyclotron res-
onance mass spectrometry. Anal.
Biochem. 329, 269–275.
Ghosh, S., Matsuoka, Y., Asai, Y., Hsin,
K. Y., and Kitano, H. (2011). Soft-
ware for systems biology: from tools
to integrated platforms. Nat. Rev.
Genet. 12, 821–832.
Gonzalez, E., and McGraw, T. E. (2009).
The Akt/PKB kinases: isoform
www.frontiersin.org November 2012 | Volume 3 | Article 418 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
specificity in metabolism and cancer.
Cell Cycle 8, 2502–2508.
Guo, S., Miyake, M., Liu, K. J., and
Shi, H. (2009). Specific inhibition of
hypoxia inducible factor 1 exagger-
ates cell injury induced by in vitro
ischemia through deteriorating cel-
lular redox environment. J. Neu-
rochem. 108, 1309–1321.
Hamanaka, R. B., and Chandel, N. S.
(2012). Targeting glucose metabo-
lism for cancer therapy. J. Exp. Med.
209, 211–215.
Handl, J., Kell, D. B., and Knowles,
J. (2007). Multiobjective optimiza-
tion in bioinformatics and compu-
tational biology. IEEE/ACM Trans.
Comput. Biol. Bioinform. 4, 279–292.
Holzhütter, H. G. (2004). The principle
of flux minimization and its applica-
tion to estimate stationary fluxes in
metabolic networks. Eur. J. Biochem.
271, 2905–2922.
Howell, J. J., and Manning, B. D. (2011).
mTOR couples cellular nutrient
sensing to organismal metabolic
homeostasis. Trends Endocrinol.
Metab. 22, 94–102.
Jiang, P., Du, W., Wang, X., Mancuso, A.,
Gao, X., Wu, M., et al. (2011). p53
regulates biosynthesis through direct
inactivation of glucose-6-phosphate
dehydrogenase. Nat. Cell Biol. 13,
310–316.
Kohn, A. D., Summers, S. A., Birn-
baum, M. J., and Roth, R. A. (1996).
Expression of a constitutively active
Akt/PKB Ser/Thr kinase in 3T3-
L1 adipocytes stimulates glucose
uptake and glucose transporter 4
translocation. J. Biol. Chem. 271,
31372–31378.
Kreeger, P. K., and Lauffenburger, D.
A. (2010). Cancer systems biology: a
network modeling perspective. Car-
cinogenesis 31, 2–8.
Kucherenko, S., Rodriguez-Fernandez,
M., Pantelides, C., Shah, N.
(2009). Monte Carlo evaluation of
derivative-based global sensitivity
measures. Reliab. Eng. Syst. Safety
94, 1135–1148.
Kuo, W., Lin, J., and Tang, T. K. (2000).
Human glucose-6-phosphate dehy-
drogenase (G6PD) gene transforms
NIH 3T3 cells and induces tumors
in nude mice. Int. J. Cancer 85,
857–864.
Lambeth, M. J., and Kushmerick, M.
J. (2002). A computational model
for glycogenolysis in skeletal muscle.
Ann. Biomed. Eng. 30, 808–827.
Land, S. C., and Tee, A. R. (2007).
Hypoxia-inducible factor 1alpha is
regulated by the mammalian target
of rapamycin (mTOR) via an mTOR
signaling motif. J. Biol. Chem. 282,
20534–20543.
Le, A., Cooper, C. R., Gouw, A. M.,
Dinavahi, R., Maitra, A., Deck, L. M.,
et al. (2010). Inhibition of lactate
dehydrogenase A induces oxidative
stress and inhibits tumor progres-
sion. Proc. Natl. Acad. Sci. U.S.A. 107,
2037–2042.
Le Novère, N., Hucka, M., Mi, H.,
Moodie, S., Schreiber, F., Sorokin, A.,
et al. (2009). The systems biology
graphical notation. Nat. Biotechnol.
27, 735–741.
Lee, B. L., Kim, W. H., Jung, J., Cho, S.
J., Park, J. W., Kim, J., et al. (2008). A
hypoxia-independent up-regulation
of hypoxia-inducible factor-1 by
Akt/PKB contributes to angiogenesis
in human gastric cancer. Carcino-
genesis 29, 44–51.
Levine, A. J., and Puzio-Kuter, A. M.
(2010). The control of the metabolic
switch in cancers by oncogenes and
tumor suppressor genes. Science 330,
1340.
Li, C., Donizelli, M., Rodriguez, N.,
Dharuri, H., Endler, L., Chelliah, V.,
et al. (2010a) BioModels Database:
an enhanced, curated and annotated
resource for published quantitative
kinetic models. BMC Syst. Biol. 4, 92.
doi:10.1186/1752-0509-4-92
Li, Y., Solomon, T. P. J., Haus, J. M.,
Saidel, G. M., Cabrera, M. E., and
Kirwan, J. P. (2010b). Computa-
tional model of cellular metabolic
dynamics: effect of insulin on glu-
cose disposal in human skeletal mus-
cle. Am. J. Physiol. Endocrinol. Metab.
298, 1198–1209.
Liebermeister, W., Uhlendorf, J., and
Klipp, E. (2010). Modular rate
laws for enzymatic reactions:
thermodynamics, elasticities and
implementation. Bioinformatics 26,
1528–1534.
Lunt, S. Y., and Vander Heiden, M. G.
(2011). Aerobic glycolysis: meeting
the metabolic requirements of cell
proliferation. Annu. Rev. Cell Dev.
Biol. 27, 441–464.
Manning, B. D., and Cantley, L. C.
(2007). Akt/PKB signaling: nav-
igating downstream. Cell 129,
1261–1274.
Marín-Hernández, A., Gallardo-Pérez,
J. C., Ralph, S. J., Rodríguez-
Enríquez, S., and Moreno-Sánchez,
R. (2009). HIF-1alpha modulates
energy metabolism in cancer cells by
inducing over-expression of specific
glycolytic isoforms. Mini Rev. Med.
Chem. 9, 1084–1101.
Marín-Hernández, A., Gallardo-Pérez,
J. C., Rodríguez-Enríquez, S., Encal-
ada, R., Moreno-Sánchez, R., and
Saavedra, E. (2011). Modeling can-
cer glycolysis. Biochim. Biophys. Acta
1807, 755–767.
Marín-Hernández, A., Rodríguez-
Enríquez, S., Vital-González, P. A.,
Flores-Rodríguez, F. L., Macías-
Silva, M., Sosa-Garrocho, M., et al.
(2006). Determining and under-
standing the control of glycolysis in
fast-growth tumor cells. Flux control
by an over-expressed but strongly
product-inhibited hexokinase. FEBS
J. 273, 1975–1988.
Mathupala, S. P., Ko, Y. H., and Ped-
ersen, P. L. (2009). Hexokinase-
2 bound to mitochondria: cancer’s
stygian link to the “Warburg effect”
and a pivotal target for effective
therapy. Semin. Cancer Biol. 19,
17–24.
Mohanti, B. K., Rath, G. K., Anan-
tha, N., Kannan, V., Das, B. S.,
Chandramouli, B. A., et al. (1996).
Improving cancer radiotherapy with
2-deoxy-d-glucose: phase I/II clini-
cal trials on human cerebral gliomas.
Int. J. Radiat. Oncol. Biol. Phys. 35,
103–111.
Mosca, E., Barcella, M., Alfieri, R.,
Bevilacqua, A., Canti, G., and
Milanesi, L. (2012). Systems biology
of the metabolic network regulated
by the Akt pathway. Biotechnol. Adv.
30, 131–141.
Nicholson, K. M., and Anderson, N.
G. (2002). The protein kinase
B/Akt/PKB signalling pathway in
human malignancy. Cell. Signal. 14,
381–395.
Novak, B., and Tyson, J. J. (1993).
Numerical analysis of a comprehen-
sive model of M-phase control in
Xenopus oocyte extracts and intact
embryos. J. Cell Sci. 106, 1153–1168.
Porporato, P. E., Dhup, S., Dad-
hich, R. K., Copetti, T., and Son-
veaux, P. (2011). Anticancer tar-
gets in the glycolytic metabo-
lism of tumors: a comprehen-
sive review. Front. Pharmacol. 2:49.
doi:10.3389/fphar.2011.00049
Pugh, C. W., and Ratcliffe, P. J.
(2003). Regulation of angiogenesis
by hypoxia: role of the HIF system.
Nat. Med. 9, 677–684.
Rathmell, J. C., Fox, C. J., Plas, D.
R., Hammerman, P. S., Cinalli,
R. M., Thompson, C. B. (2003).
Akt/PKB-directed glucose metabo-
lism can prevent Bax conformation
change and promote growth factor-
independent survival. Mol. Cell. Biol.
23, 7315–7328.
Reitzer, L. J., Wice, B. M., and Kennel, D.
(1980). The pentose cycle. Control
and essential function in HeLa cell
nucleic acid synthesis. J. Biol. Chem.
255, 5616–5626.
Saltelli, A., Chan, K., and Scott, E.
(2000). Sensitivity Analysis. Chich-
ester: Wiley.
Sarbassov, D. D., Guertin, D. A., Ali,
S. M., and Sabatini, D. M. (2005).
Phosphorylation and regulation of
Akt/PKB by the rictor-mTOR com-
plex. Science 307, 1098–1101.
Sauro, H. (2011). Enzyme Kinetics for
Systems Biology. Seattle: Ambrosius
Publishing and Future Skill Soft-
ware.
Schuster, R., and Holzhutter, H. G.
(1995). Use of mathematical mod-
els for predicting the metabolic effect
of large-scale enzyme activity alter-
ations. Application to enzyme defi-
ciencies of red blood cells. Eur. J.
Biochem. 229, 403–418.
Semenza, G. L., Roth, P. H., Fang, H. M.,
and Wang, G. L. (1994). Transcrip-
tional regulation of genes encod-
ing glycolytic enzymes by hypoxia-
inducible factor 1. J. Biol. Chem. 269,
23757–23763.
Sengupta, N., Rose, S. T., and Morgan,
J. A. (2011). Metabolic flux analy-
sis of CHO cell metabolism in the
late non-growth phase. Biotechnol.
Bioeng. 108, 82–92.
Singh, D., Banerji, A. K., Dwarakanath,
B. S., Tripathi, R. P., Gupta, J. P.,
Mathew, T. L., et al. (2005). Opti-
mizing cancer radiotherapy with
2-deoxy-d-glucose dose escalation
studies in patients with glioblastoma
multiforme. Strahlenther. Onkol.
181, 507–514.
Sobol, I. M. (1967). On the distribution
of points in a cube and approximate
evaluation of integrals. USSR Comp.
Math. Math. Phys. 7, 86–112.
Song, M. S., Salmena, L., and Pandolfi, P.
P. (2012). The functions and regula-
tion of the PTEN tumour suppressor.
Nat. Rev. Mol. Cell Biol. 13,283–296.
Tennant, D. A., Durán, R. V., and Got-
tlieb, E. (2010). Targeting metabolic
transformation for cancer therapy.
Nat. Rev. Cancer 10, 267–277.
Tyson, J. J., Chen, K., and Novak, B.
(2001). Network dynamics and cell
physiology. Nat. Rev. Mol. Cell Biol.
2, 908–916.
Vander Heiden, M. G. (2011). Target-
ing cancer metabolism: a therapeu-
tic window opens. Nat. Rev. Drug
Discov. 10, 671–684.
Vivanco, I., and Sawyers, C. L. (2002).
The phosphatidylinositol 3-Kinase
Akt/PKB pathway in human cancer.
Nat. Rev. Cancer 2, 489–501.
Wolf, A., Agnihotri, S., Micallef, J.,
Mukherjee, J., Sabha, N., Cairns,
R., et al. (2011). Hexokinase 2 is
a key mediator of aerobic glycoly-
sis and promotes tumor growth in
human glioblastoma multiforme. J.
Exp. Med. 208, 313–326.
Wullschleger, S., Loewith, R., and Hall,
M. N. (2006). TOR signaling in
Frontiers in Physiology | Systems Biology November 2012 | Volume 3 | Article 418 | 12
Research Topic: 
From structural to molecular systems biology: experimental and 
computational approaches to unravel mechanisms of kinase activity 
regulation in cancer and neurodegeneration
Topic Editor:
Matteo Barberis, 
Humboldt University Berlin, Germany; 
Max Planck Institute for Molecular Genetics, Berlin, Germany
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
growth and metabolism. Cell 124,
471–484.
Yoeli-Lerner, M., Chin, Y. R., Hansen,
C. K., and Toker, A. (2009).
Akt/PKB/protein kinase b and glyco-
gen synthase kinase-3beta signal-
ing pathway regulates cell migration
through the NFAT1 transcription
factor. Mol. Cancer Res. 7, 425–432.
Zhao, F., Mancuso, A., Bui, T. V., Tong,
X., Gruber, J. J., Swider, C. R., et al.
(2010). Imatinib resistance associ-
ated with BCR-ABL upregulation is
dependent on HIF-1alpha-induced
metabolic reprograming. Oncogene
29, 2962–2972.
Zoncu, R., Efeyan, A., and Sabatini, D.
M. (2011). mTOR: from growth sig-
nal integration to cancer, diabetes
and ageing. Nat. Rev. Mol. Cell Biol.
12, 21–35.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 01 August 2012; accepted:
13 October 2012; published online: 21
November 2012.
Citation: Mosca E, Alfieri R, Maj C,
Bevilacqua A, Canti G and Milanesi
L (2012) Computational modeling of
the metabolic states regulated by the
kinase Akt. Front. Physio. 3:418. doi:
10.3389/fphys.2012.00418
This article was submitted to Frontiers in
Systems Biology, a specialty of Frontiers
in Physiology.
Copyright © 2012 Mosca, Alfieri, Maj,
Bevilacqua, Canti and Milanesi. This is
an open-access article distributed under
the terms of the Creative Commons Attri-
bution License, which permits use, distri-
bution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org November 2012 | Volume 3 | Article 418 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
APPENDIX
DIFFERENTIAL ALGEBRAIC EQUATIONS
Here we report the list of equations that define the DAE system. Jx denotes the flux of reaction or, more generally, biochemical process
x ; V is the volume of the homogeneous compartment in which all biochemical processes take place.
d AMP
/
dt = 0
d ATP
/
dt = (−JHK + JPK − JACL + JcAK − JATPase − JPFK +JPGK − JPRPPS + JMPM − JGS) /V
d BPG
/
dt = (JGAPDH − JPGK)
/
V
d CIT
/
dt = 0
d DHAP
/
dt = (JFBA + JTPI)
/
V
d E4P
/
dt = (JTAL − JTKL2)
/
V
d F6P
/
dt = (JPGI − JPFK + JTKL2 + JTAL)
/
V
d F6P
/
dt = (JPGI − JPFK + JTKL2 + JTAL)
/
V
d F16P
/
dt = (JPFK − JFBA)
/
V
d G1P
/
dt = (JGP − JPGLM − JGS)
/
V
d G6P
/
dt = (JHK − JPGI − JG6PDH + JPGLM)
/
V
d GAP
/
dt = (JFBA − JTPI − JGAPDH + JTKL + JTKL2 − JTAL)
/
V
d GLC
/
dt = (JGLUT − JHK)
/
V
d NAD
/
dt = (JLDH − JGAPDH + JDHase)
/
V
d NADP
/
dt = (−JG6PDH − JPGDH + JDPHase)
/
V
d Pi
/
dt = 0
d PEP
/
dt = (JENO − JPK)
/
V
d PG2
/
dt = (JPGYM − JENO)
/
V
d PG3
/
dt = (JPGK − JPGYM)
/
V
d PGN
/
dt = (JG6PDH − JPGDH)
/
V
d PYR
/
dt = (JPK − JLDH − 1/y JMPM)/V
d LAC
/
dt = 0
d R5P
/
dt = (JR5PI − JTKL − JPRPPS)
/
V
d RU5P
/
dt = (JPGDH − JR5PI − JRUPE)
/
V
d X5P
/
dt = (JRUPE − JTKL − JTKL2)
/
V
d S7P
/
dt = (JTKL − JTAL)
/
V
FLUX EXPRESSIONS
For each reaction, the corresponding flux expression and the parameter values are listed below with the references to the works they
were taken from. When both the maximum rates of the forward (V f) and reverse (V b) reactions appear explicitly in the flux expression
(e.g., see PGI), V b was adjusted in agreement with the constraint imposed by the Haldane relationship (Sauro, 2011)
Vb = Vf · Kmb
/(
Keq · Kmf
)
on the basis of the optimized value of V f (Table 1), the reactant constants for the forward (K mf) and backward (K mb) reaction, and
the equilibrium constant (K eq).
Adenylate kinase
2ADP = ATP+ AMP
Common modular rate law (Liebermeister et al., 2010).
J_AK = Vf · ADP2 ·
(
1− ATP · AMP/Keq)/[(1+ ADP)2 + (1+ ATP) · (1+ AMP)− 1]
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Parameter Value Unit Reference
K eq 2.26 – Marín-Hernández et al. (2011)
Consumption of ATP (ATPase)
ATP→ ADP+ Pi
Common modular rate law (Liebermeister et al., 2010).
J_ATPase = V f · ATP
Oxidation of NADH (DHase)
NADH = NAD+H
Common modular rate law (Liebermeister et al., 2010).
J_DHase = Vf ·NADH ·
[
1−NAD/(NADH · Keq)] / [(1+NADH)+ (1+NAD)− 1]
Parameter Value Unit Reference
K eq 300 – Marín-Hernández et al. (2011) used 250
Oxidation of NADPH (DPHase)
NADPH = NADP+H
Common modular rate law (Liebermeister et al., 2010).
J_DPHase = Vf ·NADPH ·
[
1−NADP/(NADPH · Keq)]/[(1+NADPH)+ (1+NADP)− 1]
Parameter Value Unit Reference
K eq 0.2 – Adjusted
Enolase (ENO)
PG2 = PEP
The rate equation is from Marín-Hernández et al. (2011).
Vmr = Vmf
/
Keq · Kmp
/
Kms
www.frontiersin.org November 2012 | Volume 3 | Article 418 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
Parameter Value Unit Reference
K ms 0.038e-3 M Marín-Hernández et al. (2011)
K mp 0.06e-3 M Marín-Hernández et al. (2011)
K eq 1.4127 – Calculated from Marín-Hernández et al. (2011)
Fructose bisphosphate aldolase
F16P = GAP+ DHAP
Flux expression from Marín-Hernández et al. (2011).
Vmr = Vmf
/
Keq ·
(
Kdhap · Kg3p
/
Kfbp
)
A = F16P; P = DHAP; Q = GAP;
JFBA =
(
Vmf · A
/
Kfbp − Vmr · P · Q
/(
Kdhap · Kg3p
))/(
1+ A
/
Kfbp + P
/
Kdhap + Q
/
Kg3p + P · Q
/(
Kdhap · Kg3p
))
Parameter Value Unit Reference
K fbp 0.009e-3 M Marín-Hernández et al. (2011)
K dhap 0.08e-3 M Marín-Hernández et al. (2011)
K g3p 0.16e-3 M Marín-Hernández et al. (2011)
K eq 0.0018 – Calculated from Marín-Hernández et al. (2011)
Glyceraldehyde-3-phosphate dehydrogenase
GAP+NAD+ Pi = BPG+NADH+H
Flux expression from Marín-Hernández et al. (2011).
A = NAD; B = GAP; C = Pi; P = BPG; Q = NADH;
Vmr = Vmf
/
Keq · Kdpg · Knadh
/(
Kg3p · Knad · Kp
)
;
J_GAPDH = (Vmf · A · B · C/(Knad · Kg3p · Kp) −Vmr · P · Q/(Kdpg · Knadh)) / (1+ A/Knad + A · B/ (Knad · Kg3p)
+ A · B · C/(Knad · Kg3p · Kp)+ P · Q/ (Kdpg · Knadh)+ Q/Knadh)
Parameter Value Unit Reference
K nad 0.09e-3 M Marín-Hernández et al. (2011)
K g3p 0.19e-3 M Marín-Hernández et al. (2011)
K p 29e-3 M Marín-Hernández et al. (2011)
K dpg 0.022e-3 M Marín-Hernández et al. (2011)
K nadh 0.01e-3 M Marín-Hernández et al. (2011)
K eq 0.3574 – Calculated from Marín-Hernández et al. (2011)
Glucose-6-phosphate dehydrogenase
As in Holzhütter (2004) we used the sum of the consecutive reactions G6P+NADP+PGLT+NADPH+H and PGLT+PGN
G6P+NADP = PGN+NADPH+H
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Flux expression from Holzhütter (2004).
J_G6PDH = Vmax/KG6P/KNADP · (G6P ·NADP− PGN ·NADPH/Kapp)/(1+NADP · (1+ G6P/KG6P)
/KNADP + ATP/KATP +NADPH/KNADPH + BPG/KPGA23)
Parameter Value Unit Reference
K app 2000 – Holzhütter (2004)
K G6P 0.0667e-3 mM Holzhütter (2004)
K NADP 0.00367e-3 mM Holzhütter (2004)
K ATP 0.749e-3 mM Holzhütter (2004)
K NADPH 0.00312e-3 mM Holzhütter (2004)
K PGA23 2.289e-3 mM Holzhütter (2004)
Glucose transport
GLCe = GLC
Monosubstrate reversible Michaelis–Menten equation (Marín-Hernández et al., 2011).
J _glut = Vmax f ·
(
GLC_e− GLC/keq
)
/ (K Glc_e · (1+ GLC/KGlc)+ GLC_e)
Parameter Value Unit Reference
keq 1 – Marín-Hernández et al. (2011)
K Glc 9.3e-3 M Marín-Hernández et al. (2011)
K Glc_e 10e-3 M Marín-Hernández et al. (2011)
Glycogen Phosphorylase A
GLYn+ Pi = GLYm+ G1P
Flux expression from Lambeth and Kushmerick (2002), where GLYn = GLYm = GLY.
Vmax r = Vmax f · KiGLYb · KiG1P/
(
KiGLYf · KPi · Keq
)
J _GPa = (Vmax f · (GLY · Pi/ (K iGLYf · K Pi)) −Vmaxr · (GLY · G1P/ (KGLYb · K iG1P)))
/
(
1+ GLY/K iGLYf + Pi/K iPi+ GLY/K iGLYb + G1P/K iG1P +GLY · Pi/ (K iGLYf · K iPi)+ (GLY · G1P) / (K iGLYb · K iG1P))
Parameter Value Unit Reference
KGLYf 1.7e-3 M Lambeth and Kushmerick (2002)
KPi 4e-3 M Lambeth and Kushmerick (2002)
KiGLY 0.2e-3 M Lambeth and Kushmerick (2002)
KiPi 4.7e-3 M Lambeth and Kushmerick (2002)
K GLYb 0.15e-3 M Lambeth and Kushmerick (2002)
K G1P 2.7e-3 M Lambeth and Kushmerick (2002)
KiG1P 10.1e-3 M Lambeth and Kushmerick (2002)
K eq 0.42 – Lambeth and Kushmerick (2002)
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Glycogen Phosphorylase B
GLYn+ Pi = GLYm+ G1P
Flux expression from Lambeth and Kushmerick (2002), where GLYn = GLYm = GLY.
Vmax r = Vmax f · K iGLYb · KG1P/
(
K iGLYf · K iP i · Keq
)
J _GPb = (Vmaxf · (GLY · Pi/(K iGLYf · K Pi)) −Vmaxr · (GLY · G1P/(K iGLYb · KG1P)))
/ (1 + GLY/K iGLYf + Pi/K iPi + GLY/K iGLYb + G1P/K iG1P +(GLY · Pi)/(K iGLYf · K Pi) + (GLY · G1P)/(K iGLYb · KG1P))
· (AMPnH/Kamp)/(1 + AMPnH/Kamp);
Parameter Value Unit Reference
K Pi 0.2e-3 M Lambeth and Kushmerick (2002)
K iPi 4.6e-3 M Lambeth and Kushmerick (2002)
K iGLYf 15e-3 M Lambeth and Kushmerick (2002)
K G1P 1.5e-3 M Lambeth and Kushmerick (2002)
K iG1P 7.4e-3 M Lambeth and Kushmerick (2002)
K iGLYb 4.4e-3 M Lambeth and Kushmerick (2002)
nH 1.75 – Lambeth and Kushmerick (2002)
K amp 1.9e-12 M Lambeth and Kushmerick (2002)
K eq 16.62 – Lambeth and Kushmerick (2002)
Glycogen synthase
We used the sum of three reactions G1P+UTP = UDP−Glc+2Pi, UDP−Glc+GLYn = UDP+GLYm and UDP+ATP = UTP+ ADP
GLY+ G1P+ ATP = GLY+ ADP+ 2Pi
Flux expression from Li et al. (2010b).
GLYn = GLYm = GLY
J _GS=Vmaxf/Kf · G1P · ATP · GLY ·
(
1− Pi2 · ADP/(G1P · ATP · Keq)
)
/(1 + G1P · ATP · GLY/Kf + GLY · Pi2 · ADP/Kr)
Parameter Value Unit Reference
K f 1.740e-04 – Li et al. (2010b)
K r 1.580e-02 – Li et al. (2010b)
K eq 2.671e-05 – Li et al. (2010b)
Hexokinase
GLC+ ATP = ADP+ G6P
Random bi-substrate Michaelis–Menten (Marín-Hernández et al., 2011).
A = GLC; B = ATP; P = G6P; Q = ADP
J _HK = (Vmf/ (Ka · Kb) · (A · B − P · Q/Kapp)) / (1+ A/Ka + B/Kb + A · B/ (Ka · Kb)+ P/Kp + Q/Kq + P · Q
/
(
Kp · Kq
)+ A · Q/ (Ka · Kq)+ P · B/ (Kp · Kb))
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Parameter Value Unit Reference
K a 0.1 mM Marín-Hernández et al. (2011)
K b 1.1 mM Marín-Hernández et al. (2011)
K p 0.02 mM Marín-Hernández et al. (2011)
K q 3.5 mM Marín-Hernández et al. (2011)
K app 651 – Marín-Hernández et al. (2011)
Lactate dehydrogenase
PYR+NADH = LAC+NAD
The rate equation is from Marín-Hernández et al. (2011).
A = NADH, B = PYR, P = LAC, Q = NAD
Vmr = Vmf/Keq · Kp · Kq/ (Ka · Kb)
JLDH =
(
Vmf · A · B/ (alfa · Ka · Kb)− Vmr · P · Q/
(
beta · Kp · Kq
))
/
(
1+ A/Ka + B/Kb + A · B/ (alfa · Ka · Kb)+ P · Q/
(
beta · Kp · Kq
)+ P/Kp + Q/Kq ) ;
Parameter Value Unit Reference
alfa 1 – Marín-Hernández et al. (2011)
K a 0.002e-3 M Marín-Hernández et al. (2011)
K b 0.3e-3 M Marín-Hernández et al. (2011)
beta 1 - Marín-Hernández et al. (2011)
K p 4.7e-3 M Marín-Hernández et al. (2011)
K q 0.07e-3 M Marín-Hernández et al. (2011)
K eq 3.4525e+03 – Calculated from Marín-Hernández
et al. (2011)
Mitochondrial pyruvate metabolism
Common modular rate law (Liebermeister et al., 2010).
1/y PYR+ 5/ (2y)O2+ Pi+ ADP→ 3/y CO2+ 5/y H2O+ ATP
JMPM = Vf · (PYR1/y · Pi · ADP · O5/(2·y)2 · [1− (ATP · CO3/y2 )/(PYR1/y ·O5/(2·y)2 · Pi · ADP · K eq)]
/[(1+ PYR)1/y · (1+O2)5/(2·y) · (1 + Pi) · (1 + ADP) + (1 + ATP) · (1 + CO2)3/y − 1]
Parameter Value Unit Reference
K eq 106 – Adjusted
y 12.5 – Commonly accepted average ATP yield
Phosphofructokinase
F6P+ ATP = F16P+ ADP
Flux expression from Marín-Hernández et al. (2011).
A = F6P; B = ATP; P = F16P; Q = ADP.
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JPFK =

Vm ·
(
B/Katp
)
/
(
1+ (B/Katp)) · (1+ (beta · F26P) / (alfa · Kf26bp)) / (1+ (F26P/ (alfa · Kf26bp))) ·(
A · (1+ (F26P/ (alfa · Kf26bp)))) / (Kf6p · (1+ (F26P/Kf26bp))) · (1+ (A · (1+ (F26P/ (alfa · Kf26bp))))) /(
Kf6p · (1+ (F26P/Kf26bp)))3/ (L · (1+ CIT/Kcit)4 · (1+ B/Kiatp)4) /(1+ (F26P/Kf26bp))4
+ (1+ (A · (1+ (F26P/ (alfa · Kf26bp))))) /(Kf6p · (1+ (F26P/Kf26bp)))4 − ((Q · P) / (Kadp · Kfbp · Kapp) /(
Q/Kadp
)+ (P/Kfbp)+ (Q · P) / (Kadp · Kfbp)+ 1)

Parameter Value Unit Reference
K atp 0.021 mM Marín-Hernández et al. (2011)
beta 0.98 – Marín-Hernández et al. (2011)
alfa 0.32 – Marín-Hernández et al. (2011)
K f26bp 0.00084 mM Marín-Hernández et al. (2011)
K f6p 1.0 mM Marín-Hernández et al. (2011)
L 4.1 mM Marín-Hernández et al. (2011)
K cit 6.8 mM Marín-Hernández et al. (2011)
Kiatp 20 mM Marín-Hernández et al. (2011)
K adp 5 mM Marín-Hernández et al. (2011)
K fbp 5 mM Marín-Hernández et al. (2011)
K app 247 – Marín-Hernández et al. (2011)
Phosphogluconate dehydrogenase
PGN+NADP = RU5P+ CO2+NADPH+ 2H
Flux expression from Holzhütter (2004).
JPGDH = Vmax/K6PG1/KNADP · (PGN ·NADP− RU5P ·NADPH/Kapp)/((1+NADP/KNADP)
· (1+ PGN/K6PG1 + BPG/KPGA23)+ ATP/KATP +NADPH · (1+ PGN/K6PG2)/KNADPH)
Parameter Value Unit Reference
K app 141.7 – Holzhütter (2004)
K 6PG1 0.01e-3 mM Holzhütter (2004)
K 6PG2 0.058e-3 mM Holzhütter (2004)
K PGA23 0.12e-3 mM Holzhütter (2004)
K NADP 0.018e-3 mM Holzhütter (2004)
K NADPH 0.0045e-3 mM Holzhütter (2004)
K ATP 0.154e-3 mM Holzhütter (2004)
Phosphoglucoisomerase
Monoreactant reversible equation with competitive inhibition by E4P, 6PG, and FBP (Marín-Hernández et al., 2011).
G6P = F6P
Vmr = Vmf · Kf6p/
(
Keq · Kg6p
)
JPGI =
(
Vmf · G6P/Kg6p − Vmr · F6P/Kf6p
)
/
(
1+ A/Kg6p + P/Kf6p + E4P/Kery4p + F16P/Kfbp + PGN/Kpg
)
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Parameter Value Unit Reference
K g6p 0.4e-3 M Marín-Hernández et al. (2011)
K f6p 0.05e-3 M Marín-Hernández et al. (2011)
K ery4p 0.001e-3 M Marín-Hernández et al. (2011)
K fbp 0.06e-3 M Marín-Hernández et al. (2011)
K pg 0.015e-3 M Marín-Hernández et al. (2011)
K eq 5.56e-2 – Calculated from Marín-Hernández
et al. (2011)
Phosphoglucomutase
G1P = G6P
Flux expression from Lambeth and Kushmerick (2002).
Vmaxr = Vmaxf · KG6P/
(
KG1P · Keq
)
JPGLM = (Vmaxf · G1P/KG1P − Vmaxr · G6P/KG6P) / ( 1+ G1P/KG1P + G6P/KG6P)
Parameter Value Unit Reference
K eq 17.2 – Gao and Leary (2004)
K G1P 0.063e-3 M Lambeth and Kushmerick (2002)
K G6P 0.03e-3 M Lambeth and Kushmerick (2002)
Phosphoglycerate kinase
BPG+ ADP = PG3+ ATP
Flux expression from Marín-Hernández et al. (2011).
A = BPG, B = ADP, P = PG3, Q = ATP
Vmr = Vmf/Keq · Kp · Kq/ (Ka · Kb)
JPGK =
(
Vmf · A · B/ (alfa · Ka · Kb)− Vmr · P · Q/
(
beta · Kp · Kq
))
/
(
1+ A/Ka + B/Kb + A · B/ (alfa · Ka · Kb)+ P · Q/
(
beta · Kp · Kq
)+ P/Kp + Q/Kq )
Parameter Value Unit Reference
Alfa 1 – Marín-Hernández et al. (2011)
K a 0.079e-3 M Marín-Hernández et al. (2011)
K b 0.04e-3 M Marín-Hernández et al. (2011)
Beta 1 – Marín-Hernández et al. (2011)
K p 0.13e-3 M Marín-Hernández et al. (2011)
K q 0.27e-3 M Marín-Hernández et al. (2011)
K eq 11.369 – Calculated from Marín-Hernández
et al. (2011)
Pyruvate kinase
PEP+ ADP = PYR+ ATP
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The rate equation is from Marín-Hernández et al. (2011).
JPK = Vm · (B/Kadp)/(1+ (B/Kadp)) · ((A/Kpep) · (1+ (A/Kpep))3)/(((L · (1+ (Q/Kiatp))4)/(1+ (F16P/Kfbp))4)
+ (1+ (A/Kpep))4)− ((Q · P)/(Katp · Kpyr · Kapp))/(((Q/Katp)+ (P/Kpyr))+ ((Q · P)/(Katp · Kpyr))+ 1));
Parameter Value Unit Reference
K adp 0.4 mM Marín-Hernández et al. (2011)
K pep 0.014 mM Marín-Hernández et al. (2011)
L 1 – Marín-Hernández et al. (2011)
K iatp 2.5 mM Marín-Hernández et al. (2011)
K fbp 0.0004 mM Marín-Hernández et al. (2011)
K atp 0.86 mM Marín-Hernández et al. (2011)
K pyr 10 mM Marín-Hernández et al. (2011)
K app 195172 – Marín-Hernández et al. (2011)
Phosphoribosylpyrophosphate synthetase
R5P+ ATP = AMP+ PRPP
Flux expression from Holzhütter (2004).
JPRPPS = Vmax ·
(
R5P · ATP− PRPP · AMP/Kapp
)
/ ((KATP + ATP) · (KR5P + R5P))
Parameter Value Unit Reference
K app 1e5 – Holzhütter (2004)
K ATP 0.0300e-3 mM Holzhütter (2004)
K R5P 0.57e-3 mM Holzhütter (2004)
Phosphoglycerate mutase
PG3 = PG2
The rate equation is from Marín-Hernández et al. (2011).
Vmr = Vmf/Keq · Kmp/Kms
JPGYM =
(
Vmf · PG3/Kms − Vmr · PG2/Kmp
)
/
(
1+ PG3/Kms + PG2/Kmp
)
;
Parameter Value Unit Reference
K ms 0.19e-3 M Marín-Hernández et al. (2011)
K mp 0.12e-3 M Marín-Hernández et al. (2011)
K eq 1.6491 – Calculated from Marín-Hernández
et al. (2011)
Ribose-5-phosphate isomerase
RU5P = R5P
Flux expression from Schuster and Holzhutter (1995).
JR5PI = Vmax ·
(
RU5P− R5P/KeqR5PI
)
/ (RU5P+ KRu5P · (1+ R5P/KR5P))
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Parameter Value Unit Reference
K eq_R5PI 3 – Holzhütter (2004)
K Ru5P 0.78e-3 mM Holzhütter (2004)
K R5P 2.2e-3 mM Holzhütter (2004)
Ribulose-phosphate epimerase
RU5P = X5P
Flux expression from Holzhütter (2004).
JRUPE = Vmax ·
(
RU5P− X5P/KeqRUPE
)
/ (RU5P+ KRu5P · (1+ X5P/KX5P))
Parameter Value Unit Reference
K eq_RUPE 2.7 – Holzhütter (2004)
K Ru5P 0.19e-3 mM Holzhütter (2004)
K X5P 0.5e-3 mM Holzhütter (2004)
Transaldolase
S7P+ GAP = F6P+ E4P
Flux expression from Schuster and Holzhutter (1995).
JTAL = Vmax ·
(
S7P · GAP− E4P · F6P/KeqTAL
)
/((K1 + GAP) · S7P+ (K2 + K6 · F6P ) · GAP+ (K3 + K5 · F6P) · E4P
+ K4 · F6P+ K7 · S7P · E4P)
Parameter Value Unit Reference
K 1 0.00823e-3 mM Holzhütter (2004)
K 2 0.04765e-3 mM Holzhütter (2004)
K 3 0.1733e-3 mM Holzhütter (2004)
K 4 0.006095e-3 mM Holzhütter (2004)
K 5 0.8683 – Holzhütter (2004)
K 6 0.4653 – Holzhütter (2004)
K 7 2.524 – Holzhütter (2004)
K eq_TKL2 2.703 – Casazza and Veech (1986)
Transketolase
R5P+ X5P = GAP+ S7P
Flux expression from Schuster and Holzhutter (1995).
JTKL = Vmax ·
(
R5P · X5P− GAP · S7P/KeqTKL
)
/((K1 + R5P) · X5P+ (K2 + K6 · S7P) · R5P+ (K3 + K5 · S7P) · GAP
+ K4 · S7P+ K7 · X5P · GAP)
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Parameter Value Unit Reference
K 1 0.4177e-3 mM Holzhütter (2004)
K 2 0.3055e-3 mM Holzhütter (2004)
K 3 12.432e-3 mM Holzhütter (2004)
K 4 0.00496e-3 mM Holzhütter (2004)
K 5 0.41139 – Holzhütter (2004)
K 6 0.00774 – Holzhütter (2004)
K 7 48.8 – Holzhütter (2004)
K eq_TKL 2.08 – Casazza and Veech (1986)
Transketolase 2
X5P+ E4P = GAP+ F6P
Flux expression from Schuster and Holzhutter (1995).
JTKL2 = Vmax ·
(
E4P · X5P− GAP · F6P/KeqTKL2
)
/((K1 + E4P) · X5P+ (K2 + K6 · F6P) · E4P+ (K3 + K5 · F6P) · GAP
+ K4 · F6P+ K7 · X5P · GAP)
Parameter Value Unit Reference
K 1 0.00184e-3 – Holzhütter (2004)
K 2 0.3055e-3 mM Holzhütter (2004)
K 3 0.0548e-3 mM Holzhütter (2004)
K 4 0.0003e-3 mM Holzhütter (2004)
K 5 0.0287 – Holzhütter (2004)
K 6 0.1220 – Holzhütter (2004)
K 7 0.2150 – Holzhütter (2004)
K eq_TKL2 29.7 – Casazza and Veech (1986)
Triose-phosphate isomerase
GAP = DHAP
Flux expression from Marín-Hernández et al. (2011).
Vr = Vf
/
Keq · Kmp
/
Kms;
JTPI =
(
Vf · GAP
/
Kms−Vr · DHAP
/
Kmp
)/(
1+ GAP/Kms + DHAP/Kmp)
Parameter Value Unit Reference
K ms 0.51e-3 M Marín-Hernández et al. (2011)
K mp 1.6e-3 M Marín-Hernández et al. (2011)
K eq 0.3810 – Calculated from Marín-Hernández
et al. (2011)
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GENERAL MODEL PARAMETERS
Symbol Definition Value Reference
A Concentration of ATP+ADP 1.140e-02 M Marín-Hernández et al. (2011)
CO2 Carbon dioxide concentration 2.140e-02 M Bazil et al. (2010)
GLCe External glucose concentration 1.000e-02 M Reitzer et al. (1980)
F26P Fructose-1,6-bisphosphate concentration 4.200e-06 M Marín-Hernández et al. (2011)
N Concentration of NAD+NADH 1.345e-03 M Marín-Hernández et al. (2011)
NP Concentration of NADP+NADPH 1.932e-05 M Reitzer et al. (1980)
O2 Oxygen concentration 6.500e-05 M Bazil et al. (2010)
V Volume 1.000e+05 nl/mg
METABOLITE CONCENTRATIONS AT STEADY STATES H AND L
Symbol Model (H) Experimental (H) Model (L)
ADP 2.70e-03 2.70e-03b 2.83e-03
AMP 3.11e-03 4.00e-03b 3.11e-03
ATP 8.70e-03 8.70e-03b 8.57e-03
BPG 6.29e-05 9.00e-07b 5.41e-05
CIT 1.08e-03 1.70e-03b 1.08e-03
DHAP 5.53e-04 0.93e-03b 5.53e-04
E4P 9.30e-04 1.60e-05b 3.16e-05
F6P 3.62e-05 5.00e-04b 4.38e-05
F16P 3.67e-05 3.80e-04b 3.68e-04
F26P 2.13e-06 4.20e-06b 2.13e-06
G1P 3.41e-03 8.00e-05b 3.56e-05
G6P 1.09e-03 1.30e-03b 8.08e-04
GAP 1.53e-04 8.00e-05b 1.47e-04
GLC 8.97e-04 6.10e-04b 7.02e-04
GLY 2.08e-01 1.71e-01b 2.08e-01
NAD 1.34e-03 1.34e-03b 1.34e-03
NADH 5.00e-06 5.00e-06b 5.11e-06
NADP 6.12e-07 0.92e-06c 6.14e-07
NADPH 1.87e-05 1.84e-05c 1.87e-05
Pi 2.00e-02 4.00e-03b 2.00e-02
PEP 5.79e-05 3.20e-04b 5.76e-05
PG2 4.98e-06 3.00e-06b 5.02e-06
PG3 3.07e-05 6.00e-06b 1.83e-05
PGN 1.10e-04 7.50e-05b,c 1.30e-05
PRPP 1.00e-3 1.00e-3a 1.00e-3
PYR 1.83e-03 8.50e-03c 1.68e-03
LAC 1.55e-02 3.30e-02a 1.55e-02
R5P 2.74e-05 1.40e-05a 7.47e-06
RU5P 1.43e-04 4.70e-06a 1.43e-05
X5P 2.42e-04 1.60e-05c 3.50e-05
S7P 8.58e-05 7.00e-05c 3.50e-06
Values are in M unit.
aHolzhütter (2004).
bMarín-Hernández et al. (2011).
cReitzer et al. (1980).
www.frontiersin.org November 2012 | Volume 3 | Article 418 | 25
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mosca et al. Metabolic states regulated by Akt
METABOLIC FLUXES IN CONDITION H AND L
Reaction Experimental (H) Model (H) Model (L)
AK NM 0.00 0.00
ATPase NM 50.6 50.0
DHase NM 2.65 3.20
DPHase NM 2.00 1.16
FBA 10.38* 9.24 5.43
ENO 21.24* 18.65 10.90
G6PDH 1.13a 1.00 0.58
GAPDH 21.24* 18.65 10.90
GLUT 11.30a 10.00 5.98
GP NM 0.01 0.01
GS 0.11a 0.10 0.06
HK 11.30* 10.00 5.98
LDH 18.08a 16.00 7.69
MPM 39.5* 33.13 40.0
PFK 10.38* 9.24 5.43
PGDH 1.13* 1.00 0.58
PGI 10.06* 8.91 5.36
PGK 21.24* 18.53 10.90
PGLM −0.11* −0.09 −0.05
PGYM 21.24* 18.65 10.90
PK 21.24* 18.65 10.90
PRPPS 0.57a 0.50 0.47
R5PI 0.76* 0.67 0.51
RUPE 0.37* 0.33 0.07
TAL 0.16* 0.17 0.04
TKL 0.16* 0.17 0.04
TKL2 0.16* 0.17 0.04
TPI −10.38* −9.24 −5.43
Values are in nmol/min/mg unit. NM, Not measured.
aReitzer et al., 1980.
*Values calculated from the experimental data presented in Reitzer et al. (1980) on the basis of the metabolic network stoichiometry.
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